{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000010","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.651615+00:00","generated_at":"2026-06-20T15:14:44.597050+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AnaptysBio authorizes $50M stock repurchase plan; cash >$575M","bullets":["Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.","Cash, equivalents, and investments >$575M as of Dec 31, 2022.","Reiterates ~4 years of capital to execute R&D plan, excluding potential GSK royalties.","Repurchases may occur in open market under Rule 10b5-1 and 10b-18; no obligation to buy."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000010","json":"https://secwatch.observer/filing/0001370053-23-000010.json","markdown":"https://secwatch.observer/filing/0001370053-23-000010.md","text":"https://secwatch.observer/filing/0001370053-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000010/0001370053-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000010/anab-20230113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T15:14:44.597050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}